Apixaban a better choice of drug than Rivarobaxan in Atrial Fibrillation- How? - Video

Published On 2022-01-11T10:45:36+05:30 | Updated On 18 Oct 2023 3:26 PM IST

Overview

There is an interesting research which states that apixaban is a much better drug of choice than Rivaroxaban in adults with atrial fibrillation (AF) on starting a direct oral anticoagulant (DOAC) for stroke prevention.

Atrial fibrillation incidence has increased in aged populations worldwide, and increased survival with chronic diseases.

United States alone, reported atleast 3 to 6 million people have atrial fibrillation, and the numbers are projected to reach 6 to 16 million by 2050 approximately. In Europe, prevalent atrial fibrillation in 2010 was 9 million among individuals older than 55 years and is expected to reach 14 million by 2060.

It is estimated that by 2050 atrial fibrillation will be diagnosed at least in 72 million individuals in Asia, approximately 3 million with atrial fibrillation related strokes.

Speakers

Dr. Nandita Mohan

BDS, MDS( Pedodontics and Preventive Dentistry)

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Dr. Prem Aggarwal

Dr Prem Aggarwal, (MD Medicine, DNB Cardiology) is a Cardiologist by profession and also the Co-founder and Chairman of Medical. He focuses on news and perspectives about cardiology, and medicine related developments at Medical Dialogues. He can be reached out at drprem@medicaldialogues.in

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751